A recent study published in the journal SSRN by researchers at Harvard University, the University of Texas at Dallas and the Massachusetts Institute of Technology (MIT) questions if the FDA and other regulatory agencies worldwide rush certain approvals, particularly at the end of the year in a kind of “desk-clearing” activity.